Last year, researchers announced that the Alzheimer’s drug lecanemab lowered the amount of amyloid protein plaques associated with the disease in the brains of participants in a clinical trial, and slowed their cognitive decline.
Now, researchers are looking to drug combinations, vaccines and gene therapy to tackle different stages of the disease, as they forge the next generation of treatments for the condition.
This is an audio version of our Feature: Conquering Alzheimer’s: a look at the therapies of the future
Never miss an episode. Subscribe to the Nature Podcast on Apple Podcasts, Google Podcasts, Spotify or your favourite podcast app. An RSS feed for Nature Podcast is available too.
Could drugs prevent Alzheimer’s? These trials aim to find out
Alzheimer’s drug slows mental decline in trial — but is it a breakthrough?
FDA approves Alzheimer’s drug lecanemab amid safety concerns
